CJC-1295 + Ipamorelin complete guide

GH-axis research has two complementary classes of secretagogue. GHRH analogs — Sermorelin, Tesamorelin, CJC-1295 — act on the GHRH receptor (GHRH-R) on pituitary somatotrophs, releasing growth hormone through the natural cAMP/PKA pathway. GHRPs / ghrelin-mimetics — Ipamorelin, GHRP-2, GHRP-6 — act on a different receptor entirely: the growth-hormone secretagogue receptor (GHSR-1a), driving GH release through the Gα_q/11/PLC/IP₃/Ca²⁺ cascade. The two pathways are non-redundant. Activated together, the combined GH pulse exceeds the sum of either alone — a true biochemical synergy at the level of the somatotroph cell.

Among all the published combinations, CJC-1295 + Ipamorelin is the most-cited combined-peptide research design in modern GH-axis literature, and there are clean reasons for it. CJC-1295 carries a Drug Affinity Complex (DAC) modification that covalently binds serum albumin, extending half-life from minutes to days and producing week-stable plasma levels. Ipamorelin is the cleanest of the GHRPs — selective for GHSR-1a, with no meaningful elevation of cortisol, prolactin or aldosterone, unlike GHRP-6 or ghrelin itself. Pairing the longest-acting GHRH analog with the most selective GHRP yields amplified GH pulses without the side-profile that complicates older GHRP research.

This guide is a complete research-frame deep-dive on the blend as a laboratory research compound. Structure of both peptides, the DAC pharmacokinetics, the GHSR-1a selectivity argument, the dual-pathway synergy mechanism, published research on body-composition and sleep-architecture endpoints, comparison with adjacent GHRH/GHRP combinations, and laboratory-handling methodology. All language is research-frame. No protocol guidance. No clinical recommendations.

Quick reference — combined identifiers

Property	CJC-1295 (with DAC)	Ipamorelin
Class	Modified GHRH analog	Selective GHRP / ghrelin mimetic
Sequence	DAC-bound GHRH(1-29) with [D-Ala2, Gln8, Ala15, Leu27]	Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5 aa)
Molecular formula	C165H269N47O46 (with DAC)	C38H49N9O5
Molecular weight	~3367 g/mol	711.86 g/mol
CAS number	863288-34-0	170851-70-4
Origin	Modified Sermorelin (GHRH 1-29) with N-terminal stabilization + DAC for serum-albumin binding	Synthetic selective ghrelin-receptor agonist (Novo Nordisk research, 1990s)
Receptor target	GHRH-R (somatotroph receptor)	GHSR-1a (ghrelin receptor)
Half-life	~6-8 days (DAC-extended)	~2 hours
TogoPeptide vials	Pre-mixed blend cjc1295-ipa-blend (5 mg / 10 mg, 1:1 weight ratio); both compounds also available standalone

Two compounds, two pathways

The dual-class framework is the conceptual core of this blend. GHRH analogs — the Sermorelin family plus CJC-1295 and Tesamorelin — bind the GHRH receptor on pituitary somatotrophs. Receptor activation drives the canonical Gα_s/cAMP/PKA pathway, opening the somatotroph for GH secretion. GHRPs and ghrelin mimetics — Ipamorelin, GHRP-2, GHRP-6, hexarelin — bind a separate receptor on the same cell: GHSR-1a, the growth-hormone secretagogue receptor (also the endogenous ghrelin receptor). GHSR-1a activation routes through Gα_q/11/PLC/IP₃, releasing intracellular Ca²⁺ and driving GH secretion through a different intracellular cascade.

The critical point is that the two pathways are non-redundant at the somatotroph level — each amplifies the other’s signal. Published research consistently shows the combination produces 2-5× larger GH pulses than either alone in research-animal models, and Veldhuis & Bowers' three-peptide-control framework formalises this as the canonical model for GH pulsatility: GHRH input + GHRP/ghrelin input minus somatostatin tone [6].

CJC-1295 — DAC-extended GHRH

Structure modifications from Sermorelin

The CJC-1295 molecule is built on the same 29-amino-acid backbone as Sermorelin (GHRH 1-29, the minimum-active fragment of human GHRH 1-44). Four amino-acid substitutions are layered on top for protease resistance: [D-Ala², Gln⁸, Ala¹⁵, Leu²⁷]. D-Ala at position 2 blocks DPP-4 cleavage. Gln at position 8 prevents asparagine deamidation. Ala at 15 and Leu at 27 stabilise the helical core against trypsin-class cleavage.

The defining feature, however, is the DAC (Drug Affinity Complex) — a maleimidopropionic-acid moiety attached at the C-terminal Lys³⁰. The maleimide reacts covalently with the free thiol on Cys³⁴ of circulating serum albumin. The peptide is now physically bound to a 67 kDa carrier protein, which extends the half-life from Sermorelin’s roughly 10-20 minutes to CJC-1295's ~6-8 days in published research models [1]. This is the modification that makes “true” CJC-1295 a once-weekly research compound.

Pulsatility consideration

The week-long half-life is also the trade-off. With CJC-1295 elevating GHRH-receptor activation continuously, physiological GH pulsatility is partially flattened — the natural sharp peaks-and-troughs pattern smooths into a more sustained elevation. Ionescu & Frohman documented that pulsatile GH secretion does persist under continuous CJC-1295 stimulation, but the architecture shifts compared with native GHRH input [5]. This is a research-design choice: studies wanting sustained GH/IGF-1 elevation across the dosing interval prefer CJC-1295 with DAC; studies probing physiological pulse architecture lean to Sermorelin or Tesamorelin where each dose is a discrete pulse.

“With DAC” vs “without DAC” / Mod GRF 1-29

An important nomenclature point: "CJC-1295 without DAC" — also marketed as Mod GRF (1-29) or CJC-1295-NoDAC — is a related but distinct compound. It carries the same four amino-acid substitutions for protease resistance but lacks the albumin-binding DAC moiety. Half-life is ~30 minutes, much closer to Sermorelin than to true CJC-1295. The “true CJC-1295” in published research literature, including the 2006 Teichman JCEM trial that established the pharmacology, is the DAC form with week-long half-life. When research designs reference simply “CJC-1295” without qualification, the DAC form is generally meant; when they reference “Mod GRF 1-29,” the no-DAC form is specifically meant.

Ipamorelin — the selective GHRP

Structure and selectivity

Ipamorelin is a pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two non-natural building blocks give it protease resistance. Aib (α-aminoisobutyric acid) at the N-terminus blocks aminopeptidase cleavage. D-2-Nal and D-Phe are D-amino acid residues that resist standard L-specific peptidases. The C-terminus is amidated, blocking carboxypeptidase action. The result is a small, stable molecule with high affinity for GHSR-1a.

The selectivity argument is what made Ipamorelin the preferred GHRP in modern research design. Unlike GHRP-6 (which causes appetite stimulation through ghrelin-overlap effects), GHRP-2 (which elevates cortisol and prolactin), or ghrelin itself (which activates the full ghrelin receptor profile), Ipamorelin binds GHSR-1a with high affinity but does not meaningfully activate cortisol, prolactin, or aldosterone pathways at research-relevant doses [2]. This selectivity is the entire reason Ipamorelin became the canonical GHRP in research designs where cortisol confound is undesirable — which is most of them.

GHSR-1a / ghrelin receptor activation

GHSR-1a is the growth-hormone secretagogue receptor — a Gα_q/11-coupled GPCR expressed on pituitary somatotrophs (and elsewhere). Endogenously, ghrelin is its primary ligand. Synthetic GHRPs occupy the same orthosteric site but with different downstream selectivity profiles. Ipamorelin binding triggers Gα_q/11 → PLC → IP₃ → intracellular Ca²⁺ release → GH secretion. This is mechanistically parallel to GHRH-receptor activation but routes through a different intracellular cascade. Both pathways converge on the same end — GH release from somatotroph secretory granules — but they are independent inputs, which is the structural basis for combination synergy [3].

Origin: Novo Nordisk research

Ipamorelin was developed at Novo Nordisk in the 1990s as part of the broader growth-hormone-secretagogue research programme (the wider GHRP family was pioneered by Cyril Bowers at Tulane in the 1970s-80s; the selective successor compounds came out of Novo Nordisk and other industrial labs). Originally researched as a GH-deficiency clinical candidate, Ipamorelin’s published pharmacology established the “selective GHRP” framework: full GH-releasing potency, minimal off-target hormone activation. The original Raun et al. paper in European Journal of Endocrinology remains the foundational reference.

The synergy mechanism

This is the canonical research framework for the blend. CJC-1295 is the “amplifier” — sustained GHRH input that primes the pituitary. Ipamorelin is the “trigger” — selective per-dose GHSR-1a activation that converts the primed state into a measurable GH pulse. The combination produces both larger-amplitude pulses and a higher pulse frequency than either compound alone in research-animal models, with the overall IGF-1 response exceeding the simple sum of monotherapy effects.

Body-composition and lean-mass research

The published research-animal-model literature on combined GHRH/GHRP designs documents downstream effects on body composition consistent with sustained GH/IGF-1 axis activation. Reported endpoints include lean-mass markers, adipose-tissue distribution shifts, and longitudinal IGF-1 elevation. Sackmann-Sala, Berryman et al. and adjacent work review long-term GH effects on body composition in research-animal models, providing the framework for interpreting combined-peptide outcomes [4]. Published findings should be read in context — research-animal-model outcomes do not transfer directly to clinical populations, and the combined blend’s research literature is smaller and more recent than the monotherapy corpora for either CJC-1295 or Ipamorelin separately.

Sleep-architecture research

GH is normally sleep-coupled — the largest physiological GH pulse occurs during slow-wave (deep) sleep, especially in early-night cycles. Published research on combined GHRH/GHRP designs documents amplification of this nocturnal pulse and, in some research-design protocols, increased slow-wave-sleep duration. The mechanism is consistent with the broader synergy framework: sustained GHRH receptor activation (CJC-1295) raises baseline GH-release readiness, while the natural night-time GHSR-1a activity (augmented per-dose by Ipamorelin) drives larger sleep-coupled pulses. This is a research framework, not a sleep-aid claim.

Why this blend, not others

The CJC-1295 + Ipamorelin pair is the canonical GHRH/GHRP combination in modern research design because it pairs the longest-acting GHRH analog with the cleanest selective GHRP. Adjacent combinations have specific trade-offs:

Combination	Trade-off in research design
CJC-1295 + Ipamorelin (canonical)	Week-stable GHRH signal + selective GHSR-1a pulse, minimal cortisol/prolactin confound
CJC-1295 + GHRP-6	Same GHRH backbone, but GHRP-6 introduces appetite-stimulus and modest cortisol/prolactin elevation
CJC-1295 + GHRP-2	Stronger per-dose GH release than Ipamorelin pairings, but with confounding cortisol/prolactin signals
Sermorelin + Ipamorelin	Both short-acting; preserves natural pulsatility but requires multiple-per-day dosing for sustained input
Tesamorelin alone	VAT-research strength but no GHRP synergy — single-pathway activation only

The selectivity-plus-half-life pairing is the structural argument for why this specific combination became the most-cited GHRH/GHRP design. Other pairings remain in active research use, but the CJC-1295 + Ipamorelin blend is the default framework reference.

Storage and handling

Both compounds ship as lyophilized powder, supplied either as the pre-mixed blend or as standalone vials. Standard research-handling literature documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window — typically 24+ months under proper storage for both peptides.
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent. The benzyl alcohol enables multi-puncture access across approximately 28 days under refrigeration.
• Pre-mixed blend reconstitution: the cjc1295-ipa-blend vial reconstitutes at the standard ratio — both peptides resuspend together, with the final solution containing both at the labelled 1:1 weight ratio.
• Reconstituted state: refrigerate at 2–8°C immediately after reconstitution. Reconstituted shelf life ~28 days under refrigeration. Avoid freeze-thaw cycles — repeated phase changes destabilise both peptides.
• Vial inspection — clear, faintly straw-tinted solution after reconstitution. Cloudiness or particulates indicate aggregation or microbial compromise; discard and re-reconstitute fresh.

Each TogoPeptide shipment includes a per-batch Certificate of Analysis with HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, manufacture date, analysis date. See how to read a COA or reconstitution methodology for methodology details.

Cross-research lines and pairings

Within the broader GH-axis research framework, the CJC-1295 + Ipamorelin blend pairs naturally with other compounds in the same mechanism class:

• Performance Stack pairing — the blend plus Sermorelin and Tesamorelin gives full GHRH/GHRP-class coverage in a single research tier: short-acting GHRH (Sermorelin) for pulsatility studies, long-acting GHRH (Tesamorelin / CJC-1295-DAC) for sustained-elevation studies, and selective GHRP (Ipamorelin) for dual-pathway synergy studies. See the Performance Stack page for the full configuration.
• Comparison-design framework — research designs pairing the blend with Sermorelin probe the difference between week-long and minutes-long GHRH input on combined outcomes; pairings with Tesamorelin probe the visceral-adipose framework on top of dual-pathway synergy.
• Methodology articles — see Tesamorelin complete guide for the GHRH-class framework, and reconstitution methodology for diluent and sterile-handling research practice.

Closing

The CJC-1295 + Ipamorelin blend is the most-investigated combined-peptide research design in modern GH-axis literature. The DAC-extended GHRH input and the selective GHSR-1a input act through independent intracellular cascades on the same somatotroph cell — non-redundant, synergistic, and producing GH responses larger than either pathway alone. The selectivity-plus-half-life pairing is what makes this specific combination the canonical reference framework: sustained physiological GHRH signal, clean per-dose GHRP trigger, minimal off-target hormone confound.

This guide documents what published peer-reviewed research has investigated. It is structural, mechanism, and pharmacokinetic context for laboratory researchers — not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

Source the blend and individual compounds for laboratory research:

• CJC-1295 + Ipamorelin pre-mixed blend — 5 mg / 10 mg vials at 1:1 weight ratio, per-batch COA
• Ipamorelin standalone — selective GHRP, multiple vial strengths
• CJC-1295 with DAC standalone — week-stable GHRH analog
• Performance Stack — full GHRH/GHRP-class coverage tier
• Performance / GH-axis research compounds — full category listing

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.